Or Yat Sun 4
4 · ENANTA PHARMACEUTICALS INC · Filed Feb 13, 2026
Research Summary
AI-generated summary of this filing
Enanta (ENTA) CSO Or Yat Sun Receives Equity Awards; 3,413 Shares Withheld
What Happened Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals (ENTA), received equity awards that settled into 6,875 shares of Enanta common stock on February 12, 2026 (two separate awards: 1,650 and 5,225 shares). To cover tax withholding obligations, 3,413 of those shares were automatically forfeited at $14.25 per share (total value withheld = $48,635). The awards were issued at no cash cost to the reporting person (grant price $0.00), leaving a net 3,462 shares delivered to the insider.
Key Details
- Transaction date: February 12, 2026 (filed February 13, 2026) — appears timely.
- Grants: 1,650 shares (PSUs) and 5,225 shares (rTSRU) acquired at $0.00.
- Tax withholding: 3,413 shares surrendered at $14.25/share for $48,635 (coded F).
- Net shares received by insider: 3,462 shares (6,875 granted − 3,413 withheld).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Footnotes: PSUs vested based on two-year R&D milestones (F1); rTSRU vested based on relative total shareholder return vs. Nasdaq Biotech Index (F2); F3 notes the automatic forfeiture to cover withholding taxes.
Context
- PSUs and rTSRUs are performance-based awards that convert to stock when performance conditions are met; these grants are not open-market purchases or sales by the insider.
- The withholding of shares to pay taxes is a routine administrative step and does not necessarily indicate a buy or sell signal.
- This filing reports issuance and tax withholding only; there was no open-market sale or exercise-for-cash reported on this date.
Insider Transaction Report
Form 4
Or Yat Sun
Chief Scientific Officer
Transactions
- Award
Common Stock
[F1]2026-02-12+1,650→ 373,042 total - Award
Common Stock
[F2]2026-02-12+5,225→ 378,267 total - Tax Payment
Common Stock
[F3]2026-02-12$14.25/sh−3,413$48,635→ 374,854 total
Footnotes (3)
- [F1]Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F2]Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
- [F3]Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.
Signature
/s/ Matthew Kowalsky as attorney-in-fact|2026-02-13